이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

HOOKIPA Pharma 배당금

배당금 기준 확인 0/6

HOOKIPA Pharma 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.48
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

Jun 22

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Apr 28

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Mar 24

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Aug 11

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Nov 19

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Jul 25

Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

May 18

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 HOOK 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: HOOK 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

HOOKIPA Pharma 시장 대비 배당 수익률

HOOK 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (HOOK)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.8%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (HOOK)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 HOOK 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 HOOK 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 HOOK 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: HOOK 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

HOOKIPA Pharma 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

HOOKIPA Pharma Inc Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting

First quarter 2024 earnings released: EPS: US$0.11 (vs US$0.27 loss in 1Q 2023)

HOOKIPA Pharma Inc. to Report Q1, 2024 Results on May 09, 2024

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

HOOKIPA Pharma Inc., Annual General Meeting, Jun 17, 2024

HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

HOOKIPA Pharma Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

HOOKIPA Pharma Provides Non-Compliance Update

Price target decreased by 11% to US$4.17

HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024

HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024

Hookipa Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Consensus revenue estimates increase by 14%

Price target decreased by 7.6% to US$4.32

HOOKIPA Pharma Inc. Presents Positive Biomarker and Translational Data on HB-200 Monotherapy At Society for Immunotherapy of Cancer 2023

HOOKIPA Pharma Inc. to Report Q3, 2023 Results on Nov 09, 2023

Hookipa Pharma Inc. Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

HOOKIPA Pharma Inc. Announces Resignation of Christine Baker as Chief Operating Officer, Leaving on January 15, 2024

HOOKIPA Pharma Inc. Announces Management Changes

Consensus revenue estimates fall by 18%

New major risk - Shareholder dilution

Price target increased by 16% to US$5.38

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

HOOKIPA Pharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates upgraded to US$1.09 loss

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

HOOKIPA Pharma Inc. to Report Q1, 2023 Results on May 11, 2023

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Less than half of directors are independent

Price target decreased by 18% to US$4.64

Full year 2022 earnings: EPS and revenues exceed analyst expectations

HOOKIPA Pharma Receives A Letter from Nasdaq Regarding Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Appoints Katia Schlienger as Chief Medical Officer and Malte Peters to Board of Directors

Price target decreased to US$5.64

Consensus forecasts updated

Price target increased to US$7.17

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HOOKIPA Pharma Inc. to Report Q3, 2022 Results on Nov 14, 2022

Price target decreased to US$6.29

Consensus revenue estimates increase by 11%

Price target decreased to US$6.29

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HOOKIPA Pharma Inc. to Report Q2, 2022 Results on Aug 11, 2022

Food and Drug Administration Accepts Hookipa’s Investigational New Drug Application for HB-300

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

HOOKIPA Pharma Inc.(NasdaqGS:HOOK) dropped from Russell 2000 Dynamic Index

HOOKIPA Pharma Inc. Announces Executive Leadership Changes

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommend Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

Price target decreased to US$7.29

Consensus forecasts updated

Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

HOOKIPA Pharma Inc., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

HOOKIPA Pharma Inc. to Report Q1, 2022 Results on May 16, 2022

HOOKIPA Pharma Inc. Announces Promotion of Christine D. Baker to Chief Operating Officer

Price target decreased to US$8.43

HOOKIPA Pharma Inc. Announces Christoph Lengauer, A Member of the Board of Directors Will Not Stand for Re-Election

Price target decreased to US$8.43

HOOKIPA Pharma Inc. Announces Positive Preclinical Data Demonstrating Potent T Cell Responses Potential Novel Combination Use Beyond Pd-1

Hookipa: Speculative Biotech With Key Catalysts In 2022

HOOKIPA Pharma Inc. announced that it expects to receive $35 million in funding from Gilead Sciences, Inc.